Deals & Corporate Governance

  • January 08, 2024

    Novartis To Buy Merck Spin-Off Calypso Biotech For Up To $375M

    Swiss pharmaceutical giant Novartis is buying European company Calypso Biotech in a deal that could be worth up to $375 million, according to an announcement from Calypso on Monday, marking one of the earliest deals to be announced at the start of the deal frenzy expected at the J.P. Morgan Healthcare conference in San Francisco this week.

  • January 08, 2024

    Eli Lilly, Novartis Could Pump Close To $3B Into AI Drug Tech

    Eli Lilly & Co. and Novartis could invest close to $3 billion in the development of artificial intelligence for drug discovery under two new agreements with a digital biology company owned by Google's parent company.

  • January 08, 2024

    Cravath Steers J&J Buy Of Skadden-Led Ambrx In $2B Deal

    Pharmaceutical industry giant Johnson & Johnson, advised by Cravath Swaine & Moore LLP, is buying San Diego, California-based clinical-stage biopharmaceutical company Ambrx Biopharma Inc., advised by Skadden Arps Slate Meagher & Flom LLP, in an all-cash, take-private deal with a total equity value of roughly $2 billion, the two companies announced separately Monday.

  • January 05, 2024

    Pharma Co. Snags $100M To Advance Psychedelic Treatment

    The pharmaceutical arm of the nonprofit Multidisciplinary Association for Psychedelic Studies said on Friday it raised $100 million in an initial round of financing as it transitions to new leadership.

  • January 05, 2024

    ​​Boehringer Ingelheim Inks €410M Deal With Kyowa Kirin

    Pharmaceutical giant Boehringer Ingelheim announced Friday that it had entered into a €410 million ($449 million) licensing agreement with Japanese pharmaceutical company Kyowa Kirin to develop a new treatment for fibro-inflammatory diseases, the third in a string of consecutive deals Boehringer Ingelheim has announced this week.

  • January 05, 2024

    Md. Retirees Ask 4th Circ. For 2nd Shot At Drug Coverage Suit

    Retired Maryland state employees have asked the Fourth Circuit for another chance to pursue a proposed class action over the state's transition of their prescription coverage plan to Medicare Part D after their first try was dismissed last year.

  • January 05, 2024

    9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant

    A Ninth Circuit panel on Friday denied drugmaker Valeant Pharmaceuticals' request to review its decision to revive a False Claims Act suit accusing Valeant of fraudulently obtaining a patent to extend its monopoly on the drug Apriso.

  • January 05, 2024

    Attys Hopeful For Deals Pickup As JPMorgan Event Kicks Off

    Attorneys heading to the annual J.P. Morgan Healthcare Conference are hoping to strike fruitful conversations with other dealmakers regarding capital-raising and M&A prospects, aided by the backdrop of several blockbuster acquisitions in recent weeks.

  • January 05, 2024

    NC Residents Bemoan Holdups In Hospital Monopoly Case

    A group of North Carolina residents are pushing the state Business Court to move ahead with discovery in their antitrust suit against Mission Hospital and its new owners, saying the case shouldn't have to idle while they wait for a long-delayed ruling in parallel federal litigation.

  • January 05, 2024

    Former Alexion Exec Avoids Prison In Insider Trading Case

    A Manhattan federal judge sentenced a former Alexion Pharmaceuticals Inc. vice president to eight months of house arrest Friday for tipping off a childhood friend about the company's $1.4 billion purchase of Portola Pharmaceuticals in 2020, rejecting prosecutors' bid for prison time.

  • January 05, 2024

    Opioid Trust Isn't For Care Claims Trader, Trustee Argues

    A healthcare recovery and data company shouldn't be able to transact claims made against an opioid trust in Mallinckrodt's Chapter 11 bankruptcy, a trustee in the case has argued, telling a Delaware federal court that the trust is limited only to insurers and other providers of healthcare benefits.

  • January 05, 2024

    IQVIA Drops Healthcare Ad Deal After Court Pause

    Healthcare data company IQVIA has abandoned its planned purchase of Propel Media after the Federal Trade Commission convinced a court to pause the deal over concerns about the cost of advertising that targets doctors and other healthcare professionals.

  • January 05, 2024

    Healthcare-Focused PE Firm Closes $180M Fund

    Healthcare-focused private equity shop Leavitt Equity Partners, advised by Dorsey & Whitney LLP, on Friday said that it closed its third private equity fund after raising $180 million in commitments.

  • January 05, 2024

    UK Litigation Roundup: Here's What You Missed In London

    The past week in London has seen Lucasfilm use the force in a High Court appeal in a dispute over the use of the late actor Peter Cushing's likeness, defunct crypto lender Celsius bring legal proceedings against cryptocurrency insurance startup Unslashed, and the Kuwaiti pensions authority bring another lawsuit to the table in a $10 million bribery scandal involving the authority’s former boss. Here, Law360 looks at these and other new claims in the U.K.

  • January 04, 2024

    Roche Could Pay $2B In Deal To Develop Potent Cancer Drugs

    Moma Therapeutics announced Thursday that it could receive over $2 billion in milestone payments from Swiss pharmaceutical giant Roche through a new collaboration to develop powerful cancer treatments.

  • January 04, 2024

    Life Sciences Investment Firm TCG Crossover Closes $1B Fund

    TCG Crossover, also known as TCGX, announced Thursday that it has closed a new fund, raising $1 billion in capital to be invested into both private and public companies focused on drug discovery.

  • January 04, 2024

    Hospital Network Told To Provide Contracts In Antitrust Suit

    A Connecticut state judge Thursday ordered Hartford HealthCare Corp. to hand over a raft of contracts with insurers and related documents, some dating back to 2008, as part of a discovery request in a putative class action accusing the hospital network of violating antitrust and unfair trade practices laws.

  • January 04, 2024

    Chancery Rejects Injunction Barring SomaLogic Merger Vote

    Finding that risks to a $1 billion merger outweigh disputed stockholder claims of inadequate disclosures and an unfair process, a Delaware vice chancellor on Thursday refused to block a noon shareholder vote on the tie-up between SomaLogic Inc. and Standard BioTools Inc.

  • January 04, 2024

    Deals Rumor Mill: Cigna, Bain Capital, Amazon

    Cigna is seeking to unload its Medicare Advantage business for up to $4 billion, Bain Capital wants to sell antibodies manufacturer Centrient Pharmaceuticals for $1.1 billion, and Amazon could buy a stake in regional sports networks. Here, Law360 breaks down these and other notable deal rumors from the past week.

  • January 04, 2024

    Medical Tech Co. Buys Breathing Device Biz For Up To $2.5M

    Inspiration Healthcare Group PLC said Thursday that it has bought life support ventilator business Airon Corp. in a deal worth up to $2.5 million, as the British medical technology company eyes entering the "significant strategic market" in the U.S.

  • January 03, 2024

    ACTS Retirement Data Breach Suit Settlement Gets Initial OK

    A Pennsylvania federal judge gave preliminary approval Tuesday to a deal inked by ACTS Retirement Services Inc. to settle claims it failed to protect the personal information of nearly 21,000 people exposed in an April 2022 data breach.

  • January 03, 2024

    5 January Argument Sessions Benefits Attys Should Watch

    The Fifth Circuit will hear arguments this month over whether the Affordable Care Act's anti-discrimination mandate covers sexual orientation and gender identity, and Goldman Sachs workers will seek to revive a class action over proprietary retirement investments.

  • January 03, 2024

    No Fines Over Physician Retirement Offer, HHS OIG Says

    A health system that makes voluntary offers to all physician partners reaching the age of 67 to purchase their partnership units if they stop practicing medicine does not breach the federal Anti-Kickback Statute, the U.S. Department of Health and Human Services said in an advisory opinion posted Wednesday.

  • January 03, 2024

    Chancery Mulls Call To Block $1B SomaLogic Merger

    A Delaware vice chancellor reported plans to rule Thursday morning on a preliminary injunction bid from a proposed class of stockholders targeting the merger of SomaLogic Inc. and Standard BioTools Inc., hours before a noon Eastern time stockholder meeting on the hotly contested biopharmaceutical industry tie-up.

  • January 03, 2024

    Esperion Snags $125M Deal With Daiichi On Cholesterol Drug

    Esperion Therapeutics Inc. on Wednesday announced a $125 million deal with a Japanese pharmaceutical giant to resolve Esperion's demand for $300 million from the company over Esperion's cholesterol reduction drugs.

Expert Analysis

  • FTC's Criminal Liaison Unit Enhances Merger Risks

    Author Photo

    As it enters its second year, the Criminal Liaison Unit within the Federal Trade Commission’s Bureau of Competition may streamline and sharpen efforts to detect and refer substantive and procedural violations to prosecutors, increasing the chances of a merger review uncovering potential criminal activity, say attorneys at Norton Rose.

  • Short Message Data Challenges In E-Discovery

    Author Photo

    As short message platforms increasingly dominate work environments, lawyers face multiple programs, different communication styles and emoji in e-discovery, so they must consider new strategies to adapt their processes, says Cristin Traylor at Relativity.

  • Thomas Report Is Final Straw — High Court Needs Ethics Code

    Author Photo

    As a recent report on Justice Clarence Thomas' ongoing conflicts of interest makes evident, Supreme Court justices should be subject to an enforceable and binding code of ethics — like all other federal judges — to maintain the credibility of the institution, says Erica Salmon Byrne at Ethisphere.

  • Joint Representation Ethics Lessons From Ga. Electors Case

    Author Photo

    The Fulton County district attorney's recent motion to disqualify an attorney from representing her elector clients, claiming a nonconsentable conflict of interest, raises key questions about representing multiple clients related to the same conduct and highlights potential pitfalls, say Hilary Gerzhoy and Grace Wynn at HWG.

  • Lawyer Discernment Is Critical In The World Of AI

    Author Photo

    In light of growing practical concerns about risks and challenges posed by artificial intelligence, lawyers' experience with the skill of discernment will position them to help address new ethical and moral dilemmas and ensure that AI is developed and deployed in a way that benefits society as a whole, says Jennifer Gibbs at Zelle.

  • Cannabis Considerations In Debt Collection, Credit Reporting

    Author Photo

    While companies that collect debts arising from cannabis purchases, and consumer reporting agencies that furnish information concerning such debts, may not be governed by consumer protection laws, they should probably act like it by implementing compliance programs that heed state and federal requirements, say Corey Scher and Joshua Horn at Fox Rothschild.

  • Don't Forget Alumni Engagement When Merging Law Firms

    Author Photo

    Neglecting law firm alumni programs after a merger can sever the deep connections attorneys have with their former firms, but by combining good data management and creating new opportunities to reconnect, firms can make every member in their expanded network of colleagues feel valued, say Clare Roath and Erin Warner at Troutman Pepper.

  • Interstate Cannabis Commerce May Be In Reach, With Caveats

    Author Photo

    California is the latest state to lay the groundwork for interstate cannabis commerce agreements, which may offer a solution to the overabundance of product in legal adult-use markets and survive constitutional challenges — but even then, obstacles to a national market will remain, say Adam Horowitz and Harry Berezin at Goodwin.

  • Without Stronger Due Diligence, Attys Risk AML Regulation

    Author Photo

    Amid increasing pressure to mitigate money laundering and terrorism financing risks in gatekeeper professions, the legal industry will need to clarify and strengthen existing client due diligence measures — or risk the federal regulation attorneys have long sought to avoid, says Jeremy Glicksman at the Nassau County District Attorney’s Office.

  • Abortion Pill Rulings Will Hinder FDA Authority

    Author Photo

    Although the Fifth Circuit recently stayed a Texas federal court's ruling that invalidated the U.S. Food and Drug Administration's approval of a commonly used abortion medication, several points made by the courts are worth considering for their potentially chilling effect on FDA authority and the challenges they may create for the life sciences industry, say attorneys at Morgan Lewis.

  • Cannabis Labor Peace Laws Lay Fertile Ground For Unions

    Author Photo

    State legislatures are increasingly passing cannabis laws that encourage or even mandate labor peace agreements as a condition for licensure, and though open questions remain about the constitutionality of such statutes, unionization efforts are unlikely to slow down, says Peter Murphy at Saul Ewing.

  • Every Lawyer Can Act To Prevent Peer Suicide

    Author Photo

    Members of the legal industry can help prevent suicide among their colleagues, and better protect their own mental health, by learning the predictors and symptoms of depression among attorneys and knowing when and how to get practical aid to peers in crisis, says Joan Bibelhausen at Minnesota Lawyers Concerned for Lawyers.

  • Building On Successful Judicial Assignment Reform In Texas

    Author Photo

    Prompt action by the Judicial Conference could curtail judge shopping and improve the efficiency and procedural fairness of the federal courts by implementing random districtwide assignment of cases, which has recently proven successful in Texas patent litigation, says Dabney Carr at Troutman Pepper.